Table 3.
Ever use of specific antiretroviral medications by insulin resistance status.
| Characteristic | HOMA-IR trigger status | ||||
| Yes (N = 25) | No (N = 50) | Total (N = 75) | P value* | ||
| HAART ever use | No | 0 (0%) | 2 (4%) | 2 (3%) | 0.550 |
| Yes | 25 (100%) | 48 (96%) | 73 (97%) | ||
| Regimen includes PI + RTV or KAL ever use | No | 6 (24%) | 9 (18%) | 15 (20%) | 0.553 |
| Yes | 19 (76%) | 41 (82%) | 60 (80%) | ||
| d4T ever use | No | 3 (12%) | 13 (26%) | 16 (21%) | 0.235 |
| Yes | 22 (88%) | 37 (74%) | 59 (79%) | ||
| TDF ever use | No | 10 (40%) | 27 (54%) | 37 (49%) | 0.329 |
| Yes | 15 (60%) | 23 (46%) | 38 (51%) | ||
| ZDV ever use | No | 3 (12%) | 5 (10%) | 8 (11%) | 1.000 |
| Yes | 22 (88%) | 45 (90%) | 67 (89%) | ||
| 3TC ever use | No | 1 (4%) | 5 (10%) | 6 (8%) | 0.657 |
| Yes | 24 (96%) | 45 (90%) | 69 (92%) | ||
| NVP ever use | No | 12 (48%) | 29 (58%) | 41 (55%) | 0.466 |
| Yes | 13 (52%) | 21 (42%) | 34 (45%) | ||
| ABC ever use | No | 15 (60%) | 27 (54%) | 42 (56%) | 0.805 |
| Yes | 10 (40%) | 23 (46%) | 33 (44%) | ||
| DDI ever use | No | 5 (20%) | 18 (36%) | 23 (31%) | 0.191 |
| Yes | 20 (80%) | 32 (64%) | 52 (69%) | ||
| RTV ever use | No | 7 (28%) | 11 (22%) | 18 (24%) | 0.578 |
| Yes | 18 (72%) | 39 (78%) | 57 (76%) | ||
| ATV ever use | No | 22 (88%) | 39 (78%) | 61 (81%) | 0.361 |
| Yes | 3 (12%) | 11 (22%) | 14 (19%) | ||
| EFV ever use | No | 13 (52%) | 27 (54%) | 40 (53%) | 1.000 |
| Yes | 12 (48%) | 23 (46%) | 35 (47%) | ||
Fisher's Exact test/Kruskal Wallis test was used for categorical analyses. 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; d4T, stavudine; DDI, didanosine; EFV, efavirenz; HOMA-IR, homeostatic model assessment of insulin resistance; KAL, Iopinavir/ritonavir; NVP, nevirapine; PI, protease inhibitor; RTV, ritonavir; TDF, tenofovir; ZDV, zidovudine.
*P ≤ 0.05.